APPLIED GENETIC TECHNOLOGIES

Applied Genetic Technologies is a clinical-stage biotechnology company that uses a proprietary gene therapy platform to develop transformational genetic therapies for patients suffering from rare and debilitating diseases. The company focuses on the field of ophthalmology, where it has clinical programs in X-linked retinitis pigmentosa and achromatopsia. The company also has preclinical programs in optogenetics and adrenoleukodystrophy, which is a disease of the central nervous system (CNS), and several other ophthalmology, CNS and otology indications. The company has developed technological capabilities in the design, construction and manufacture of viral vectors using adeno-associated virus technology.
  • TickerAGTC
  • ISINUS03820J1007
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States
 PRESS RELEASE
AGTC APPLIED GENETIC... (Health Care)

AGTC Clinical Trial Investigators to Present Data from Ongoing XLRP an...

AGTC Clinical Trial Investigators to Present Data from Ongoing XLRP and Achromatopsia Phase 1/2 Trials at the Fourteenth International Symposium on Retinal Degeneration Dr. Rachel Huckfeldt and Dr. Paul Yang to Present 12-Month Findings and Analysis from AGTC’s Clinical Trials GAINESVILLE, Fla. and CAMBRIDGE, Mass., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare inherited retinal diseases, today announced a p...

 PRESS RELEASE
AGTC APPLIED GENETIC... (Health Care)

AGTC to Present at the 2021 Cantor Fitzgerald Virtual Global Healthcar...

AGTC to Present at the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference GAINESVILLE, Fla. and CAMBRIDGE, Mass., Sept. 27, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare inherited retinal diseases (IRDs), today announced that Sue Washer, President and Chief Executive Officer of AGTC, will be participating in a fireside chat at the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference at 1:20pm ET on Thurs...

David Nierengarten ... (+2)
  • David Nierengarten
  • Dennis Pak
 PRESS RELEASE
AGTC APPLIED GENETIC... (Health Care)

AGTC Provides Financial Results for the Fourth Quarter and Year Ended ...

AGTC Provides Financial Results for the Fourth Quarter and Year Ended June 30, 2021 -Data from ongoing clinical trials in XLRP and ACHM shows evidence of clinical activity and tolerability; multiple data readouts expected in 2021 and 2022- -Pre-Clinical programs moving to IND enabling animal studies- -Company adds experienced industry veterans to board and management team- -Company to host management update and webcast today at 4:30pm ET- GAINESVILLE, Fla. and CAMBRIDGE, Mass., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology...

 PRESS RELEASE
AGTC APPLIED GENETIC... (Health Care)

AGTC to Host Fourth Quarter and 2021 Fiscal Year End Financial Results...

AGTC to Host Fourth Quarter and 2021 Fiscal Year End Financial Results Conference Call and Webcast on September 23, 2021 GAINESVILLE, Fla. and CAMBRIDGE, Mass., Sept. 16, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare inherited retinal diseases (IRDs), today announced that it will report financial results for the quarter and year ended June 30, 2021 after the market closes on Thursday, September 23, 2021. AGTC management...

 PRESS RELEASE
AGTC APPLIED GENETIC... (Health Care)

AGTC Clinical Trial Investigators to Present Data from Ongoing XLRP an...

AGTC Clinical Trial Investigators to Present Data from Ongoing XLRP and Achromatopsia Phase 1/2 Trials at the Fourteenth International Symposium on Retinal Degeneration Dr. Rachel Huckfeldt and Dr. Paul Yang to Present 12-Month Findings and Analysis from AGTC’s Clinical Trials GAINESVILLE, Fla. and CAMBRIDGE, Mass., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare inherited retinal diseases, today announced a p...

 PRESS RELEASE
AGTC APPLIED GENETIC... (Health Care)

AGTC to Present at the 2021 Cantor Fitzgerald Virtual Global Healthcar...

AGTC to Present at the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference GAINESVILLE, Fla. and CAMBRIDGE, Mass., Sept. 27, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare inherited retinal diseases (IRDs), today announced that Sue Washer, President and Chief Executive Officer of AGTC, will be participating in a fireside chat at the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference at 1:20pm ET on Thurs...

David Nierengarten ... (+2)
  • David Nierengarten
  • Dennis Pak
 PRESS RELEASE
AGTC APPLIED GENETIC... (Health Care)

AGTC Provides Financial Results for the Fourth Quarter and Year Ended ...

AGTC Provides Financial Results for the Fourth Quarter and Year Ended June 30, 2021 -Data from ongoing clinical trials in XLRP and ACHM shows evidence of clinical activity and tolerability; multiple data readouts expected in 2021 and 2022- -Pre-Clinical programs moving to IND enabling animal studies- -Company adds experienced industry veterans to board and management team- -Company to host management update and webcast today at 4:30pm ET- GAINESVILLE, Fla. and CAMBRIDGE, Mass., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology...

 PRESS RELEASE
AGTC APPLIED GENETIC... (Health Care)

AGTC to Host Fourth Quarter and 2021 Fiscal Year End Financial Results...

AGTC to Host Fourth Quarter and 2021 Fiscal Year End Financial Results Conference Call and Webcast on September 23, 2021 GAINESVILLE, Fla. and CAMBRIDGE, Mass., Sept. 16, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare inherited retinal diseases (IRDs), today announced that it will report financial results for the quarter and year ended June 30, 2021 after the market closes on Thursday, September 23, 2021. AGTC management...

 PRESS RELEASE
AGTC APPLIED GENETIC... (Health Care)

AGTC Clinical Trial Investigators to Present Data from Ongoing XLRP an...

AGTC Clinical Trial Investigators to Present Data from Ongoing XLRP and Achromatopsia Phase 1/2 Trials at the Fourteenth International Symposium on Retinal Degeneration Dr. Rachel Huckfeldt and Dr. Paul Yang to Present 12-Month Findings and Analysis from AGTC’s Clinical Trials GAINESVILLE, Fla. and CAMBRIDGE, Mass., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare inherited retinal diseases, today announced a p...

 PRESS RELEASE
AGTC APPLIED GENETIC... (Health Care)

AGTC to Present at the 2021 Cantor Fitzgerald Virtual Global Healthcar...

AGTC to Present at the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference GAINESVILLE, Fla. and CAMBRIDGE, Mass., Sept. 27, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare inherited retinal diseases (IRDs), today announced that Sue Washer, President and Chief Executive Officer of AGTC, will be participating in a fireside chat at the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference at 1:20pm ET on Thurs...

David Nierengarten ... (+2)
  • David Nierengarten
  • Dennis Pak
 PRESS RELEASE
AGTC APPLIED GENETIC... (Health Care)

AGTC Provides Financial Results for the Fourth Quarter and Year Ended ...

AGTC Provides Financial Results for the Fourth Quarter and Year Ended June 30, 2021 -Data from ongoing clinical trials in XLRP and ACHM shows evidence of clinical activity and tolerability; multiple data readouts expected in 2021 and 2022- -Pre-Clinical programs moving to IND enabling animal studies- -Company adds experienced industry veterans to board and management team- -Company to host management update and webcast today at 4:30pm ET- GAINESVILLE, Fla. and CAMBRIDGE, Mass., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology...

 PRESS RELEASE
AGTC APPLIED GENETIC... (Health Care)

AGTC to Host Fourth Quarter and 2021 Fiscal Year End Financial Results...

AGTC to Host Fourth Quarter and 2021 Fiscal Year End Financial Results Conference Call and Webcast on September 23, 2021 GAINESVILLE, Fla. and CAMBRIDGE, Mass., Sept. 16, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare inherited retinal diseases (IRDs), today announced that it will report financial results for the quarter and year ended June 30, 2021 after the market closes on Thursday, September 23, 2021. AGTC management...

 PRESS RELEASE
AGTC APPLIED GENETIC... (Health Care)

AGTC Clinical Trial Investigators to Present Data from Ongoing XLRP an...

AGTC Clinical Trial Investigators to Present Data from Ongoing XLRP and Achromatopsia Phase 1/2 Trials at the Fourteenth International Symposium on Retinal Degeneration Dr. Rachel Huckfeldt and Dr. Paul Yang to Present 12-Month Findings and Analysis from AGTC’s Clinical Trials GAINESVILLE, Fla. and CAMBRIDGE, Mass., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare inherited retinal diseases, today announced a p...

 PRESS RELEASE
AGTC APPLIED GENETIC... (Health Care)

AGTC to Present at the 2021 Cantor Fitzgerald Virtual Global Healthcar...

AGTC to Present at the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference GAINESVILLE, Fla. and CAMBRIDGE, Mass., Sept. 27, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare inherited retinal diseases (IRDs), today announced that Sue Washer, President and Chief Executive Officer of AGTC, will be participating in a fireside chat at the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference at 1:20pm ET on Thurs...

David Nierengarten ... (+2)
  • David Nierengarten
  • Dennis Pak
 PRESS RELEASE
AGTC APPLIED GENETIC... (Health Care)

AGTC Provides Financial Results for the Fourth Quarter and Year Ended ...

AGTC Provides Financial Results for the Fourth Quarter and Year Ended June 30, 2021 -Data from ongoing clinical trials in XLRP and ACHM shows evidence of clinical activity and tolerability; multiple data readouts expected in 2021 and 2022- -Pre-Clinical programs moving to IND enabling animal studies- -Company adds experienced industry veterans to board and management team- -Company to host management update and webcast today at 4:30pm ET- GAINESVILLE, Fla. and CAMBRIDGE, Mass., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology...

 PRESS RELEASE
AGTC APPLIED GENETIC... (Health Care)

AGTC to Host Fourth Quarter and 2021 Fiscal Year End Financial Results...

AGTC to Host Fourth Quarter and 2021 Fiscal Year End Financial Results Conference Call and Webcast on September 23, 2021 GAINESVILLE, Fla. and CAMBRIDGE, Mass., Sept. 16, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare inherited retinal diseases (IRDs), today announced that it will report financial results for the quarter and year ended June 30, 2021 after the market closes on Thursday, September 23, 2021. AGTC management...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch